<DOC>
	<DOCNO>NCT00467012</DOCNO>
	<brief_summary>To investigate efficacy , safety , pharmacokinetics R435 paclitaxel administer concomitantly patient metastatic breast cancer .</brief_summary>
	<brief_title>Phase Ⅱ Clinical Study R435 ( Bevacizumab ) Combination With Paclitaxel Patients With Inoperable Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>At least 20 year old obtain write informed consent Advanced breast cancer ( StageⅣ ) Inoperable metastatic breast cancer HER2 negative At least one measurable lesion base RECIST criterion No previous chemotherapy metastatic breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Inoperable metastatic breast cancer</keyword>
</DOC>